Pneumococcal conjugate second or third-dose vaccines (PCVc) in Senegal
Senegal: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 91.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Senegal, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Senegal recorded 91.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025.
That represents a change of up 2.2% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Senegal peaked at 93.0% in 2016 and was at its lowest, 0.0%, in 2008.
Senegal ranks 61st of 194 countries on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Senegal, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 81.0% | — |
| 2015 | 89.0% | +9.9% |
| 2016 | 93.0% | +4.5% |
| 2017 | 92.0% | -1.1% |
| 2018 | 92.0% | +0.0% |
| 2019 | 91.0% | -1.1% |
| 2020 | 82.0% | -9.9% |
| 2021 | 83.0% | +1.2% |
| 2022 | 92.0% | +10.8% |
| 2023 | 92.0% | +0.0% |
| 2024 | 91.0% | -1.1% |
| 2025 | 91.0% | +0.0% |
Senegal compared with similar countries
- Senegal's 91.0% is above the median for lower middle income countries, which is 84.0%, 1.1× the median. (47 countries reporting)
- Senegal's 91.0% is above the median for Sub-Saharan Africa, which is 82.5%, 1.1× the median. (48 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 53.8% | 0.0% | 93.0% | 10 |
| 2020s | 88.5% | 82.0% | 92.0% | 6 |
Countries ranked near Senegal
More health data for Senegal
- Un projection of annual infant deaths, annual growth rate -1.58 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.7598 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 835.5 deaths per 1,000 people (2090)
- Number of infants who die before age 1 2,496 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 3 (2025)
- Population ages 00-04, female, annual growth rate 2.42 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0658 units per person (2025)
- Population ages 00-04, male, annual growth rate 1.29 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Senegal?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Senegal was 91.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Senegal?
- The highest recorded value was 93.0% in 2016.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Senegal?
- The lowest recorded value was 0.0% in 2008.
- How does Senegal rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Senegal ranks 61st out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Senegal?
- Over the last ten years it is up 2.2%. The long-run trend across the full record is volatile.
- Where does this Senegal data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).